The integration of Ayurvedic wound-healing adjuncts into the framework of microsurgical practice presents a novel and promising therapeutic avenue. This review synthesizes current scientific literature, clinical research, and mechanistic insights regarding the use of traditional Ayurvedic formulations as complementary agents alongside advanced microsurgical techniques for complex wound management. Emphasis is placed on translational potential, clinical outcomes, and evidence-based recommendations for healthcare professionals seeking to optimize wound healing through multimodal approaches.
Wound management in the context of microsurgery remains a challenging clinical endeavor, particularly for chronic, non-healing, or complex wounds. While advances in flap coverage, microvascular anastomosis, and perioperative care have improved outcomes, adjunctive therapies that enhance tissue regeneration and reduce complications are increasingly sought after. Ayurveda, the ancient Indian system of medicine, offers a repertoire of botanicals and formulations with established wound-healing properties. Recent scientific investigations have begun to elucidate the molecular mechanisms and clinical efficacy of these adjuncts. This review explores the evidence supporting the integration of Ayurvedic agents into microsurgical wound care, with a focus on their mechanistic rationale, safety profile, and clinical utility.
Non-healing wounds, such as diabetic foot ulcers, pressure injuries, and traumatic wounds, constitute a significant global health burden. The prevalence of chronic wounds is rising in aging populations and those with comorbidities like diabetes and vascular disease. Despite advances in microsurgical reconstruction, complications such as flap necrosis, infection, and delayed healing persist, necessitating novel adjunctive strategies. In India and many parts of Asia, Ayurvedic remedies are routinely employed in both rural and tertiary care settings, underscoring the need for scientific integration and standardization in modern practice.
Wound healing is a complex, orchestrated process involving hemostasis, inflammation, proliferation, and remodeling. In chronic wounds, dysregulation of cytokine signaling, impaired angiogenesis, and persistent infection hinder progression to healing. Microsurgical interventions aim to restore vascularity and coverage, but local tissue ischemia and systemic metabolic disturbances can limit success. Several Ayurvedic agents such as Curcuma longa (turmeric), Centella asiatica (gotu kola), and Honey have demonstrated anti-inflammatory, antioxidant, and pro-angiogenic effects, providing a mechanistic basis for their adjunctive use in wound healing.
Patients at risk for poor wound healing include those with diabetes mellitus, peripheral vascular disease, immunosuppression, advanced age, malnutrition, and smoking history. Surgical site factors such as poor perfusion, infection, and tension also increase risk. Recognizing these risk factors is essential for patient selection and tailoring adjunctive strategies, including the use of Ayurvedic agents with anti-microbial and vasoprotective properties.
Chronic and complex wounds present with non-healing edges, persistent exudate, necrosis, and signs of local infection. In microsurgical settings, partial or complete flap loss, delayed epithelialization, and persistent inflammation are common complications. Clinical evaluation should include assessment of vascular status, wound bed quality, and systemic factors influencing healing potential.
Diagnosis of wound-healing complications relies on clinical examination, Doppler ultrasonography for vascular assessment, microbial cultures for infection, and laboratory evaluation of glycemic and nutritional status. In select cases, imaging modalities such as CT angiography or MRI may be warranted to assess deep tissue involvement. Accurate diagnosis guides both surgical and adjunctive therapeutic strategies.
Standard microsurgical management involves meticulous debridement, vascularized tissue transfer, infection control, and optimization of systemic factors. Ayurvedic wound-healing adjuncts can be integrated as topical applications, oral formulations, or dressings. Jatyadi taila, Yashtimadhu (licorice), and Neem extracts have demonstrated efficacy in reducing wound bioburden, promoting granulation, and accelerating epithelialization in both preclinical and clinical studies. Practical considerations include standardization of dosing, sterility, compatibility with conventional dressings, and monitoring for allergic reactions.
Recent research has focused on the isolation of bioactive compounds from Ayurvedic plants, elucidation of their molecular targets, and development of advanced delivery systems such as hydrogels and nanofiber dressings. Randomized controlled trials have begun to evaluate the efficacy of these adjuncts in the context of diabetic foot ulcers, burns, and post-surgical wounds, with promising results. Synergistic effects with negative pressure wound therapy and growth factor dressings are also under investigation. Standardization and quality assurance of Ayurvedic products remain critical challenges for widespread clinical adoption.
International guidelines for wound management currently emphasize evidence-based conventional therapies, but increasing recognition of integrative approaches is evident in consensus statements and expert reviews. Multidisciplinary wound care teams are encouraged to consider adjunctive modalities with demonstrated safety and efficacy. For Ayurvedic agents, recommendations include use of standardized, quality-controlled formulations, close monitoring for adverse effects, and integration as part of a comprehensive, individualized treatment plan. Further large-scale clinical trials are needed to establish definitive guidelines.
The integration of Ayurvedic wound-healing adjuncts into microsurgical practice offers a scientifically grounded, clinically relevant strategy for optimizing outcomes in complex wound care. Current evidence supports their adjunctive use in select patient populations, with demonstrated benefits in reducing infection, promoting angiogenesis, and accelerating healing. Future directions include rigorous clinical trials, mechanistic studies, and development of standardized protocols to guide safe and effective integration into modern surgical practice.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation